United Therapeutics Corporation (UTHR) Releases Earnings Results, Misses Expectations By $-0.32 EPS

United Therapeutics Corporation (UTHR) reported quarterly earnings results on Thursday, Apr-28-2016. The company reported $3.02 earnings per share for the quarter, missing the analyst consensus estimate by $-0.32. Analysts had a consensus of $3.34. The company posted revenue of $369.00 million in the period, compared to analysts expectations of $397.24 million. The company’s revenue was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. United Therapeutics Corporation was Downgraded by Ladenburg Thalmann to ” Neutral” on Apr 29, 2016. Shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Sector Perform” and Lowered the Price Target to $ 122 from a previous price target of $150 .Shares were Reiterated by Wedbush on Mar 28, 2016 to “Outperform” and Lowered the Price Target to $ 229 from a previous price target of $238 .

United Therapeutics Corporation opened for trading at $117.11 and hit $119.19 on the upside on Wednesday, eventually ending the session at $117.68, with a gain of 0.20% or 0.23 points. The heightened volatility saw the trading volume jump to 7,94,026 shares. Company has a market cap of $5,337 M.

In a different news, on Apr 25, 2016, Martine A Rothblatt (Chairman & Co-CEO) sold 5,546 shares at $116.01 per share price. According to the SEC, on Apr 4, 2016, Raymond Dwek (director) sold 3,000 shares at $110.79 per share price. On Mar 3, 2016, Tommy G Thompson (director) sold 3,000 shares at $126.54 per share price, according to the Form-4 filing with the securities and exchange commission.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

United Therapeutics Corporation

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.